Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication.

Next Previous
Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms VERSE
  • Sponsors Genentech

    • Most Recent Events

    • 25 Feb 2019 Results of post-hoc analysis assessing stability of eosinophil levels from four studies (LUTE, VERSE, LAVOLTA I and LAVOLTA II) presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 13 Jun 2016 This trial was prematurely terminated in Germany, Hungary, Spain,Slovakia and Italy according to the European Clinical Trials Database.
    • 18 May 2016 Results (pooled analysis of this and other two studies) assessing correlation between the change in these pharmacodynamics biomarkers and the change in FEV1 presented at the 112th International Conference of the American Thoracic Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top